Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Gene Ther. 2013 Jan 10;20(4):450–459. doi: 10.1038/gt.2012.101

TABLE 2. Neutralizing Antibodies in Serum and CSF and Vector Persistence.

Subject Serum NAb Titer* CSF NAb titer CSF CSF
pre-
screen		 at injection 4 weeks
post inj.		 at
injection		 4 weeks
post-inj.		 vg at 2 hours
post-injection
(per mL)		 circulating
vg at
2 hrs*
101 NT <1:2 (<1:2) 1:2048
(1:2048)		 NT NT NT NT
102 NT 1:32
(1:128)		 1:1024 (1:4) NT NT NT NT
103 NT 1:32
(1:128)		 <1:2 (1:1024) NT NT NT NT
104 NT 1:2 (1:8) 1:1024
(>1:2048)		 NT NT NT NT
303 <1:2 <1:2 1:256 <1:2 <1:2 NT NT
304 <1:2 <1:2 >1:2048 <1:2 <1:2 NT NT
201 1:32 1:32 1:1024 <1:2 <1:2 <1×104 <0.0001%
202 1:128 1:128 1:1024 <1:2 1:4 3.31×105 <0.0001%
203 <1:2 1:4 1:1024 <1:2 <1:2 8.02×105 <0.0001%
204 <1:2 <1:2 1:256 <1:2 <1:2 3.30×108 0.0007%
205 <1:2 1:8 1:256 <1:2 <1:2 6.96×105 <0.0001%
206 <1:2 <1:2 1:64 <1:2 <1:2 <1×104 <0.0001%

Abbreviations: CSF = cerebrospinal fluid, NAb = neutralizing antibody, inj. = injection, vg = vector genome, hrs = hours, NT = not tested (sample not available)

*

Values are for NAb titers against AAV9. NAb titers against AAV2.5 are indicated in parentheses when tested.

*

Assuming 12 mL of CSF per animal and an even distribution of AAV particles throughout the entire 12 mL, circulating vg in the CSF was calculated as the percentage of the total vg injected, per 12 mL (1.5×1011 vg per mL CSF for low dose, 4.6×1011 vg per mL CSF for high dose).